Vivani Medical, Inc. (NASDAQ:VANI - Get Free Report) Director Gregg Williams purchased 1,587,301 shares of the firm's stock in a transaction on Monday, June 15th. The stock was acquired at an average price of $1.26 per share, with a total value of $1,999,999.26. Following the completion of the transaction, the director owned 36,119,086 shares in the company, valued at approximately $45,510,048.36. This trade represents a 4.60% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Gregg Williams also recently made the following trade(s):
- On Friday, May 15th, Gregg Williams purchased 1,587,301 shares of Vivani Medical stock. The stock was acquired at an average price of $1.26 per share, with a total value of $1,999,999.26.
- On Wednesday, April 15th, Gregg Williams purchased 1,587,301 shares of Vivani Medical stock. The stock was acquired at an average price of $1.26 per share, with a total value of $1,999,999.26.
Vivani Medical Stock Up 3.5%
VANI opened at $1.17 on Wednesday. Vivani Medical, Inc. has a twelve month low of $0.92 and a twelve month high of $1.92. The company has a fifty day moving average of $1.21 and a 200-day moving average of $1.25. The stock has a market cap of $100.90 million, a PE ratio of -2.92 and a beta of 2.31.
Vivani Medical (NASDAQ:VANI - Get Free Report) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.08) earnings per share for the quarter, hitting the consensus estimate of ($0.08). Sell-side analysts anticipate that Vivani Medical, Inc. will post -0.3 EPS for the current fiscal year.
Analyst Ratings Changes
Several equities research analysts have recently weighed in on VANI shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of Vivani Medical in a research report on Tuesday, June 9th. HC Wainwright decreased their price objective on shares of Vivani Medical from $4.00 to $3.50 and set a "buy" rating for the company in a research report on Tuesday, March 31st. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $3.50.
Get Our Latest Report on Vivani Medical
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Tudor Investment Corp ET AL bought a new position in Vivani Medical during the fourth quarter worth $1,127,000. Marshall Wace LLP bought a new position in Vivani Medical during the fourth quarter worth $174,000. State Street Corp boosted its stake in Vivani Medical by 12.5% during the fourth quarter. State Street Corp now owns 144,865 shares of the company's stock worth $178,000 after acquiring an additional 16,070 shares in the last quarter. Jane Street Group LLC bought a new position in Vivani Medical during the fourth quarter worth $60,000. Finally, Renaissance Technologies LLC boosted its stake in Vivani Medical by 118.4% during the fourth quarter. Renaissance Technologies LLC now owns 97,985 shares of the company's stock worth $121,000 after acquiring an additional 53,127 shares in the last quarter. 6.78% of the stock is owned by institutional investors.
About Vivani Medical
(
Get Free Report)
Vivani Medical Solutions, Inc (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.
The company's flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
